Thyrocare TechnologiesNSE:THYROCARE -0.29%87 ROA % is 25.22% as of Mar. 2026, which is 38% above its 10-year median of 18.28. GuruFocus rates NSE:THYROCARE with a GF Score™ of 87/100 and a GF Value™ of ₹393.35 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Thyrocare Technologies ranks better than 95.79% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Thyrocare Technologies's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹1,885 Mil.
Thyrocare Technologies's average Total Assets over the quarter that ended in Mar. 2026 was ₹7,472 Mil. Therefore, Thyrocare Technologies's annualized ROA % for the quarter that ended in Mar. 2026 was 25.22%.
The historical rank and industry rank for Thyrocare Technologies's ROA % or its related term are showing as below:
NSE:THYROCARE'
s ROA % Range Over the Past 10 Years
Min: 10.09 Med: 18.28 Max: 30.54
Current: 23.08
During the past 13 years, Thyrocare Technologies's highest ROA % was 30.54%. The lowest was 10.09%. And the median was 18.28%.
NSE:THYROCARE's ROA % is ranked better than 95.79% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.37
vs NSE:THYROCARE: 23.08
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Thyrocare Technologies's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies ROA % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's ROA % distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Thyrocare Technologies (NSE:THYROCARE) has a ROA % of 25.22% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Thyrocare Technologies and its competitors. This is 38% above median its historical median of 18.28. Over the past decade, Thyrocare Technologies' ROA % has ranged from 10.09 to 30.54. According to the industry distribution chart, Thyrocare Technologies ranks #9 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 4.2%.
Is Thyrocare Technologies' ROA % too high?
Thyrocare Technologies' current ROA % of 25.22% is 38% above median its 10-year median of 18.28. Over the past 10 years, this metric has ranged from a low of 10.09 to a high of 30.54. Based on the distribution chart, Thyrocare Technologies ranks #9 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Thyrocare Technologies has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' ROA % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #9 out of 214 companies for ROA %. This places Thyrocare Technologies in the top 4% of its industry — outperforming the majority of peers. Historically, Thyrocare Technologies' own ROA % has ranged from 10.09 to 30.54 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Diagnostics & Research company?
A good ROA % depends on the Medical Diagnostics & Research industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Thyrocare Technologies and its competitors. Thyrocare Technologies's current ROA % is 25.22%, which is 38% above median its own 10-year median of 18.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹393.35, compared to a current price of ₹555.60 — trading 41.2% above its estimated fair value. The current ROA % is 25.22%, which is 38% above median its 10-year median of 18.28. Thyrocare Technologies' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current ROA % is 25.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹555.60 is trading 41.2% above its estimated GF Value™ of ₹393.35.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
ROA %: 25.22% (38% above median its 10-year median of 18.28)
GF Value™: ₹393.35 vs. price of ₹555.60 (41.2% above fair value)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
87GF Score
Get the complete analysis for NSE:THYROCARE
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
